EP0792283A1 - Herstellung von peptidnukleinsäuren (pnas) und analogen durch einsatzvon submonomeren - Google Patents

Herstellung von peptidnukleinsäuren (pnas) und analogen durch einsatzvon submonomeren

Info

Publication number
EP0792283A1
EP0792283A1 EP95939958A EP95939958A EP0792283A1 EP 0792283 A1 EP0792283 A1 EP 0792283A1 EP 95939958 A EP95939958 A EP 95939958A EP 95939958 A EP95939958 A EP 95939958A EP 0792283 A1 EP0792283 A1 EP 0792283A1
Authority
EP
European Patent Office
Prior art keywords
nucleobase
agent
submonomer
protected
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95939958A
Other languages
English (en)
French (fr)
Inventor
Lutz S. Richter
Ronald N. Zuckermann
Thomas Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of EP0792283A1 publication Critical patent/EP0792283A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates generally to chemical synthesis technologies. More particularly, the present invention relates to the synthesis of N-substituted oligomers and particularly to Peptide Nucleic Acids (PNAs) and analogues to form poly-PNAs.
  • PNAs Peptide Nucleic Acids
  • amide polymers with nucleobase substituents also known as poly-PNAs
  • the described amide polymers included (a) nylon-based oligonucleotide analogues with a polyamide backbone; (b) polyamide oligonucleotide analogues with an alternating serine-glycine backbone; and (c) polyamide oligonucleotide analogues with an N-aminoethylglycine backbone.
  • the PNA containing the N-aminoethylglycine backbone was shown to hybridize to complementary oligonucleotides obeying the Watson-Crick hydrogen bonding rules. See Egholm et al., Nature 365:566-568 (1993).
  • a PNA containing oligomer was also effective in direct analysis of single base mutation by polymerase chain reaction (PCR). This method described in Orum et al., Nuc Acids Res 2K23V 5332-5336 (1993), took advantage of the higher thermal stability of poly- PNA binding to nucleic acids to detect single base mutations.
  • One aspect of the invention relates to a method of synthesizing PNA monomers using three submonomers, referred herein to as acylating agents, displacing agents, and nucleobase agents.
  • the method to produce a monomer comprises:
  • L— a— C— Y comprising a leaving group, L, capable of nucleophilic displacement, a backbone R., and a carbonyl group;
  • Ammo Am.no Qro ⁇ p Oraup comprising a first and second amino group, wherein said second amino group is protected;
  • the invention further relates to a method of synthesizing PNA polymers by repeating the method of synthesizing the monomer. Before the method is repeated, the second amino group is deprotected and then acylated with an acylating agent. When the steps (b) - (f) are repeated, the submonomers can be substituted with any desired submonomer to obtain polymers of varying composition.
  • Another method for synthesizing a PNA monomer is a four step cycle comprising two acylating agents, one displacing agent, and an altered nucleobase, e.g. a persilylated nucleobase.
  • the method comprises:
  • Another object of the invention is a PNA monomer compound comprising a non- natural nucleobase of the following structure:
  • Yet another object of the invention is a PNA polymer of comprising at least one non-natural nucleobase of the following structure:
  • oligomer includes polymers such as poly-PNAs, produced by the process of the invention, including homopolymers, copolymers, and interpolymers of any length. More specifically, oligomers may be comprised of a single repeating monomer, two alternating monomer units, two or more monomer units randomly and/or deliberately spaced relative to each other. Regardless of the type of poly-PNAs produced, the poly-PNAs of the invention are produced by the same general procedure which includes repeating a three-step cycle (described below in detail) wherein a new monomer unit is added in each cycle until an oligomer of desired length is obtained.
  • the oligomer is preferably 1-100 monomers, more preferably 2-50, or 2-20, and most preferably 2-10 monomers.
  • acylating agent refers to an acylating reagent used in the method of the invention.
  • acylating agents also referred to as “acyl submonomers”
  • acyl submonomers comprise a reactive carbonyl or carbonyl equivalent connected by a backbone, R_, to a leaving group.
  • the reactive carbonyl or carbonyl equivalent reacts with the second amino group of the submonomer displacing agent or amine bound substrate.
  • the backbone, R, with the backbone of the displacing agent, Ra together will be of sufficient length and flexibility to permit the nucleobases or binding agents of the oligomer to hybridize with target polynucleotides, or to bind to the desired protein, such as polymerase or DNA binding protein.
  • Suitable acyl submonomers include, without limitation, haloacetic acid, 3-halo-propionic acid, 2- halopropionic acid, 2-haloethyl isocyanate, 2-halomethyl-benzoic acid, 4-halomethyl-2- methoxybenzoic acid, 5-bromomethyl-pyridine-2-carboxylic acid, halocrotonic, 2-haloethyl- haloformate, halomethyl-benzoic acid, and the like.
  • a “leaving group” refers to a moeity capable of nucleophilic displacement by an amine, e.g., R-NH 2 . Any leaving group can be used here provided it is readily removed by nucleophilic displacement. Non-limiting examples of leaving groups useful in the invention include halo, such as bromo, chloro, iodo, O-tosyl, O-triflyl, O-mesyl, and the like.
  • Carbonyl or carbonyl equivalent includes, without limitation, carboxylic acids, esters, anhydrides, acyl halides, and isocyantes (in the synthesis of polycarbamates of the invention), which include a carbonyl group or are readily converted to include a carbonyl group.
  • Esters used will generally be "reactive" forms.
  • a carbonyl group will generally be represented
  • O ll_ by A thioester is also an example of a carbonyl equivalent.
  • Both the acyl and nucleobase submonomers contain a carbonyl or carbonyl equivalent for acylation. These acylation agents may be more potent in the presence of additional agents such as carbod ⁇ mide.
  • a "displacing agent" or “displacing submonomer” refer to a compound containing a first amino group connected by a backbone, Ra, to a second amino group. The first amino group capable of (1) effecting a nucleophilic displacement of the leaving group in an acyl submonomer and (2) being acylated by a nucleobase submonomer.
  • the second amino group is protected to prevent the second group from reacting during acylation by a nucleobase submonomer.
  • the protection also prevents the second amino group from reacting during nucleophilic displacement.
  • the backbone, R with the backbone of the displacing agent, R «, together will be of sufficient length and flexibility to permit the nucleobases or binding agents of the oligomer of the instant invention to bind with a desired protein, such as a polymerase or DNA binding protein, or hybridize with a desired target polynucleotides.
  • nucleobase agent also referred to as a "nucleobase submonomer” is a compound comprising a nucleobase or binding agent with at least one reactive carbonyl or carbonyl group equivalent.
  • a linker can be included in the submonomer between the nucleobase and carbonyl group.
  • nucleobase includes adenine, cytosine, guanine, thymine, and uracil, and refers to any substituent that can bond non-covalently with polynucleotides, such as DNA or RNA, or with other components, such as proteins, that naturally occurring polynucleotides interact with. Such non-covalent bonds include, for example, hydrogen bonding or hydrophobic interactions. These substituents exhibit one or more properties that are similar to naturally occurring nucleobases. These characteristics include an ability to participate in base pairing, structural similarity, etc.
  • PNA to polynucleotide interaction can be assayed by standard polynucleotide hybridization procedures. Examples of such assays range from annealing experiments to Southern or Northern blots to PCR assays. Detection assays of PNA interaction with other components, such as proteins, will vary and will be chosen for convenience. For example, a PNA that inhibits polymerase activity can be easily measured by standard polymerase assay. Alternatively, if the PNA is to bind irreversibly to the polymerase, other analytical techniques, such as gel electrophoresis, can be also be used.
  • nucleobases include "naturally occurring" ones, adenine, cytosine, guanine, thymine, and uracil.
  • nucleobases are substantially planar heterocyclic compounds comprising one to three rings.
  • modifications include alkylated purines or pyrimidines, acylated purines or pyrimidines, and other heterocycles.
  • Other groups included in the term nucleobase are intercalating agents, which are usually flat aromatic rings.
  • intercalating agents include without limitation: acridine, anthracene, indole, quinoline, isoquinoline, quinones, dihydroquinones, anthracyclines, tetracyclines, anthracyclinone, etc.
  • non-naturally occurring nucleobases include isocytosine and isoguanine, formulas shown below:
  • nucleobases are described in Benner et al, U.S. Pat. No. 5,432,272, herein incorporated by reference.
  • Binding agents are radicals that will modify the target molecule, which short of destroying the target molecule, cannot be reversed. Binding agents, unlike nucleobases, may not exhibit any characteristics similar to those of naturally occurring nucleobases.
  • DNA interactive agents are one example of binding agents. These agents can modify DNA by covalent bonding, breaking the DNA, or by causing crosslinking of the DNA. Examples of DNA interactive agents include, but are not limited to, protected and unprotected derivatives of nitrogenous mustards, cis-plantinum, and enediyne-derivatives. A linker of the nucleobase submonomer can be included between the nucleobase and the carbonyl group.
  • the linker may be wanted to help position the nucleobase in the desired conformation, which permits it to interact with, for example, the target nucleobase or protein.
  • the linker can be of any composition to provide the desired length and flexibility. Examples of linkers include hydrocarbons, hydrocarbyl and hydrocarbylene substituents with none, one, or two hydrogens removed respectively. These substituents may include, for example, nitrogen, sulfur, and oxygen atoms, as well as hydrogen and carbon.
  • the structure of the linker is as follows.
  • Ri, R ⁇ , Ra;, and R is a bond to the adjacent carbon or a radical which does not substantially sterically inhibit synthesis or monomer/oligomer activity; preferably, the radicals is hydrogen or an alkyl from one to four carbons;
  • Preferred R' groups are saturated hydrocarbons between 0-4 carbons; even more preferably, 1-2 carbons.
  • altered nucleobase is a nucleobase which has been altered to activate, so that the compound react with an acyl submonomer to displace the leaving group. By displacing the leaving group, the altered nucleobase can be incorporated into the monomer/oligomer.
  • the protected amino group bound to a substrate utilized to initiate solid phase monomer or oligomer synthesis or the second amino group of the displacing agent can be either a primary or secondary amine.
  • substituents are designated R, R-, or R 2 in the structures of the present application.
  • R can be of any composition.
  • R will not substantially sterically hinder synthesis or monomer/oligomer activity or function.
  • R is not so bulky that it substantially impedes hydrogen bonding for the desired degree of hybridization. Further considerations for choosing R include its tendency to sterically inhibit synthesis.
  • R examples include hydrocarbon, hydrocarbyl and hydrocarbylene substituents with none, one, or two hydrogens removed, respectively. These substituents may include, for example, nitrogen, sulfur, and oxygen atoms, as well as hydrogen and carbon. Further, these substituents may be saturated or unsaturated, aliphatic, alicyclic or aromatic. When rings are included the structure, usually one, two or three rings are included. The rings may be fused or bridged or spiro-fused.
  • R is a radical containing 12 or fewer carbon atoms, 4 or fewer nitrogen atoms, 4 or fewer oxygen atoms, and 2 or fewer sulfur atoms. More preferably, R is a radical is alkyl containing 6 or fewer carbon atoms; most preferably, R is hydrogen.
  • the spacer between the nucleobases is comprised of the following structure:
  • R, and R are the backbones of the acylating and displacing agent.
  • the spacer between the nucleobase is preferably of a length and flexibility to permit, for example, hydrogen bond base pairing between the nucleobases of the invention of the desired target polynucleotide.
  • the dimensions of the backbones can be chosen to conform to the known measurements of double stranded DNA. According to X-ray crystallography data, the double stranded DNA helix is approximately 2 nm thick and completes a 360° turn every 10 nucleotides. The nucleotides are stacked 0.34 nm apart in the double helix.
  • PNA polymers can be constructed to these dimensions, hybridization assays, such as Southern blots, can be used to determine if the PNA polymers can effectively anneal with native polynucleotides.
  • PNA monomers and oligomers can be, for example, inhibitors of enzymes and polynucleotide regulatory proteins.
  • the backbones can be chosen to enhance such inhibitor qualities by testing various constructs in protein/PNA binding assays.
  • the backbones of the acylating and displacing agent, R. and R d can include without limitation hydrocarbon radicals such as alkyl, aryl, and arylalkyl moieties. These groups may be saturated or unsaturated, aliphatic, alicyclic or aromatic. Structures comprising ring structures, usually include one, two or three rings, which may be fused, or bridged or spiro- fused.
  • R. and Rd are hydrocarbon backbones such as ethylene.
  • acylating and displacing agents which together can create oligomers with sufficient length and flexibility to bind to natural polynucleotides.
  • Preferred acylating agents of this example include those of the following formula:
  • Preferred displacing agents to be utilized with the acylating agents of this example are of either two following formula:
  • Suitable A*, Di, and ⁇ include hydrocarbon, hydrocarbyl and hydrocarbylene substituents with none, one, or two hydrogens removed, respectively. These substituents may include, for example, nitrogen, sulfur, and oxygen atoms, as well as hydrogen and carbon. Further, these substituents may be saturated or unsaturated, aliphatic, alicyclic or aromatic. When rings are included the structure, usually one, two or three rings are included. The rings may be fused or bridged or spiro-fused.
  • R is a radical containing 12 or fewer carbon atoms, 4 or fewer nitrogen atoms, 4 or fewer oxygen atoms, and 2 or fewer sulfur atoms. More preferably, R is a radical is alkyl containing 6 or fewer carbon atoms; most preferably, R is hydrogen.
  • a radical designated R- is a terminal group that can be at either terminus of the monomers or oligomers of the instant invention.
  • This radical is not critical to the invention and can be chosen at convenience from a variety of substituents.
  • R. can be a protecting group, or an amino acid; DNA interacting agent; or even a cholesterol substituent to confer hydrophobicity. Because this R. is a radical at the terminus of the monomer or oligomer, Rt generally will not substantially interfere with the hybridizing or inhibiting properties of the monomer/oligomer.
  • the "activity" of a monomer or oligomer of the instant invention will be, for example, the ability of the monomer/oligomer to hybridize with naturally occurring polynucleotides or proteins.
  • a monomer/oligomer will be considered active if can act as an inhibitor, e.g., a polymerase inhibitor.
  • a group is "protected" when any group is reversibly altered to prevent it from participating in an undesired reaction or bonding, usually in a synthesis reaction. When desired, the group can be deprotected to resume it original configuration. Groups can be protected with protecting groups to prevent, for example, reaction or bonding of carboxylic acids, thiols, and the like. Such groups and their preparation and introduction are conventional in the art and include salts, esters and the like.
  • a “substrate” or “solid support” is a conventional solid support material used in peptide synthesis.
  • a substrate can act as a protecting group.
  • Non-limiting examples of such substrates or supports include a variety of support resins and connectors to the support resins such as those which are photocleavable, DKP-forming linkers (DKP is diketopiperazine; see, e.g., WO90/09395 incorporated herein by reference), TFA-cleavable, HF-cleavable, fluoride ion cleavable, reductively cleavable and base-labile linkers.
  • Examples or solid support material include controlled pore glass, polystyrene co-polymers, polyacrylamide, silica, polyethyleneglycol, polyethylene and polypropylene grafts.
  • PNA monomers and oligomers can be synthesized utilizing the three step cycle described herein.
  • Each N-substituted PNA monomer can be synthesized directly on a solid substrate (support) from three reactants: acylating agent, displacing agent, and the nucleobase agent.
  • Step 1 Acylation
  • the backbone of the monomer is assembled in the first two steps of the synthesis cycle.
  • the first reaction is an acylation step where the carbonyl group of the acylating agent reacts with an amine.
  • the acylating agent comprises a carbonyl group; a backbone, R.; and a leaving group, L.
  • the second step is a nucleophilic displacement of the leaving group by the first amino group of the displacing agent.
  • the displacing agent comprises a first and a second amino group and a backbone, Rd.
  • the first amino group is a primary amine, and the second step produces a secondary amine.
  • the third step is another acylation in which the nucleobase agent reacts with the first amino group of the displacing agent to produce a tertiary amide.
  • the nucleobase agent comprises of a carbonyl group; an optional linker; and a nucleobase, R-,
  • Monomers and polymers can be synthesized utilizing either solution or solid phase methods.
  • a protected primary or secondary amine is provided.
  • the amine is protected to ensure that synthesis proceeds in the desired direction.
  • monomers and polymers are synthesized on a substrate or solid support.
  • the initial amine is attached to a solid support is utilized to initiate synthesis with an acylating agent.
  • the amine may be a primary or secondary amine.
  • alkyl, aryl, and arylalkyl groups are examples of substituents of preferred secondary amines.
  • Substrates to be utilized are those conventional solid support material used in peptide synthesis.
  • solid support material examples include controlled pore glass, polystyrene co ⁇ polymers, polyacrylamide, silica, polyethylene and polypropylene grafts.
  • a linker can be placed between the support and the amino group, poly-lysine, for example.
  • a variety of support bound resins including a cleavable linkers can be used, for example, p- methylbenzhydrylamine-resin-HCl or benzhydrylamine-resin-HCl; Bachem, Torrance, California, USA.
  • synthesis of oligomers or monomers begins with a primary amine bound to a support and an acylating agent.
  • a preferred substrate comprising a primary amine is, fluorenylmethoxy-carbonyl-4-methoxy-4'-(y-caA ⁇ linked to alanyl-aminomethyl resin, the resin comprising chloromethylated polystyrene, 1% divinylbenzene, 1% DVB cross-linked.
  • Acylating submonomers have been generally defined above.
  • acylating agents for the present invention, halo-crotonic, 2-halo-propionic acid, 2-halo-ethyl-haloformate, ⁇ -haloalkyl carboxylic acid, halo-methyl benzoic acid, haloalkyl sulfonic acid, and 2-haloalkyl sulfonyl chloride.
  • the acylating agent will be in excess of the substrate bound amine by about 1.01 to 10 fold; more preferably, in about 3 to about 10 fold excess; even more preferably, in about 10 fold excess.
  • the concentration will also vary depending on the conditions and quantities to be used. Typically, if bromoacetic acid is used, it will be at a concentration of between about 0.1 M to about 5 M; more typically, about 0.5 M.
  • An activation agent can be included to facilitate acylation.
  • activating agents include, without limitation, alkylphosphonic anhydrides, such as propane phosphonic anhydride; carbodiimides, such as d ⁇ sopropylcarbod ⁇ mide (DIC) and dicyclohexylcarbodiimide (DCC); uronium salts, such as HBTU, TBTU, HATU, TNTU, TSTU; phophonium salts, such as BOP, PyBOP, PyClOP,PyBrOP, PyNOP, PyFOP; carbonyld ⁇ midazole (CDI) and derivatives, such as dimethylated CDI; EEDQ; HOBt, and N- hydroxysuccinimides.
  • alkylphosphonic anhydrides such as propane phosphonic anhydride
  • carbodiimides such as d ⁇ sopropylcarbod ⁇ mide (DIC) and dicyclohexylcarbodiimide (DCC)
  • uronium salts such as HBTU, TBTU,
  • concentration of such activating agents will vary depending on the acylating submonomer and the amine to be reacted.
  • concentration of the activating agent will be approximately the same as the concentration of bromoacetic acid.
  • Solvents for solid phase synthesis are preferably dipolar and non-protic or non- polar.
  • examples of such solvents include without limitation, dimethylforamide (DMF), dimetiiylsulfoxide (DMSO), dichloromethane, dichloroethane, and N-methyl morpholine.
  • DMF dimethylforamide
  • DMSO dimetiiylsulfoxide
  • dichloromethane dichloroethane
  • N-methyl morpholine N-methyl morpholine.
  • this acylation reaction is performed at room temperature and atmospheric pressure. Though the reaction may not be driven to completion, the occurrence of unwanted side reactions is acceptable. Higher temperatures, such as 40°C - 50°C can be utilized to drive the reaction to completion. However, at these temperatures, the occurrence of unwanted side reactions can increase to affect the overall yield.
  • the time allowed for the components to react can vary depending on the temperature, pressure, reactants, and other components used.
  • the time can vary from 5 minutes to 24 hours.
  • the time given is about 30 minutes at room temperature and atmospheric pressure.
  • the substrate bound amine is deprotected if necessary.
  • the resin is washed thoroughly with the solvent alone.
  • the appropriate amount of solvent containing the acylating submonomer and activating agent is added.
  • the solution and resin are agitated during the reaction by bubbling, for example, argon or nitrogen.
  • displacing agent is added to displace the leaving group, now bound to the support.
  • Displacing submonomers have been generally defined above. The following are preferred compounds to be used as displacing agents for the present invention, 1 -
  • protecting groups that can be utilized to protect the amino group are, without limitation, p-methoxybenzyloxycarbonyl; 2(3,4 dimethoxyphenyl) prop-2- pyloxycarbonyl; 2-nitro-4,5-dimethoxybenzyloxycarbonyl; t-butoxycarbonyl (tBOC); vinyloxycarbonyl; and allyloxycarbonyl.
  • Solvents for solid phase synthesis are preferably dipolar and non-protic or non- polar.
  • examples of such solvents include without limitation, dimethylforamide (DMF), dimethylsulfoxide (DMSO), dichloromethane, dichloroethane, and N-methyl morpholine.
  • DMSO dimethylforamide
  • DMSO dimethylsulfoxide
  • dichloromethane dichloroethane
  • N-methyl morpholine N-methyl morpholine.
  • 4-(methoxybenzyloxy)carbonyl-ethylenediamine is utilized as the displacing agent for solid phase synthesis
  • DMSO is the preferred solvent.
  • the optimum ratio of these reactants will vary depending on the specific displacing agent used.
  • One factor to consider is that one equivalent of acid is generated from the nucleophilic displacement. The resulting acid can decrease the yield of the reaction by protonating the displacing agent. This problem can be circumvented by adding a base that does not disrupt the reaction.
  • the agent will be in excess of the substrate by about 1.01 to 40 fold; more preferably, in about 3 to about 20 fold excess; even more preferably, in about 10 fold excess.
  • the concentration will also vary depending on the conditions and quantities to be used. Typically, if 4- (met oxybenzyloxy)cari)onyl-ethylenediamine is used, it will be at a concentration of between about 0.1 M to about 10 M; more typically, about 0.5 M.
  • the displacement reaction is performed at room temperature and atmospheric pressure. Though the reaction may not be driven to completion, the occurrence of unwanted side reactions is acceptable. Higher tempertures, such as 40°C-50°C, can be utilized to decrease the reaction time.
  • the reaction time for the displacement step is somewhat longer thaN the acylation times.
  • the reactant time is preferably between about 20 minutes and about 12 hours; more preferably, about 1 hour to 4 hours; even more preferably, the reaction time is about two hours.
  • the final step of the cycle is another acylation reaction.
  • the beads are drained and washed with the buffer of the displacement step and then washed wit the buffer of the final step.
  • Nucleobase submonomers have been generally defined above. The following ar preferred compounds to be used as nucleobase agents for the present invention.
  • nucleobase submonomer may be in excess of the substrate bound amine by about 1.01 to 20 fold; more preferably, in about 3 to about 10 fold excess; even more preferably, in about 10 fold excess.
  • the concentration of them will also vary depending on the conditions and quantities to be used. Typically, if a thymidine nucleobase agent is used, for example, the submonomer will be at a concentration of between about 0.1 M to about 10 M; more typically, between about 0.2 M and about 0.5 M.
  • an activation agent can be included to facilitate acylation.
  • the activation agents to be used for the first step can also be utilized for this acylation step.
  • Solvents for solid phase synthesis are preferably dipolar and non-protic.
  • examples of such solvents include without limitation, dimethylsulfoxide (DMSO), dichloromethane, dichloroethane, and N-methyl morpholine.
  • DMSO dimethylsulfoxide
  • dichloromethane dichloroethane
  • N-methyl morpholine for this step, a 1:1 mixture of DMSO and N-methyl-morpholine is preferred.
  • this acylation reaction is performed at room temperature and atmospheric pressure. Though the reaction may not be driven to completion, the occurrence of unwanted side reactions is acceptable. Higher temperatures, such as 40°C - 50°C can be utilized to drive the reaction to completion. However, at these temperatures, the occurrence of unwanted side reactions can increase to affect the overall yield.
  • the time allowed for the components to react can vary depending on the temperature, pressure, reactants, and other components used. The time can vary from 5 minutes to 24 hours. Preferably, the time given for the reaction is about 30 minutes at room temperature and
  • the desired nucleobase also can be incorporated into the monomer/oligomer in two steps rather than one acylating step.
  • the first amino group of the displacing agent can be reacted with a second acyl submonomer, where R, is the linker of desired length and flexibility to place the nucleobase into the wanted conformation.
  • R is the linker of desired length and flexibility to place the nucleobase into the wanted conformation.
  • an altered nucleobase can be provided to displace the leaving group of the second acylating agent to incorporate the nucleobase into the monomer/oligomer.
  • An example of an altered nucleobase is a persilylated nucleobase.
  • the acylating reaction is performed under similar conditions as the nucleobase agent addition.
  • the agent will be in excess of the substrate by about 1.01 to 10 fold; more preferably, in about 3 to about 10 fold excess; even more preferably, in about 10 fold excess.
  • the concentration will also vary depending on the conditions and quantities to be used. Typically, if persilylated nucleobase is used, it will be at a concentration of between about 0.1 M to about 10 M; more typically, about 0.5 M.
  • Solvents for solid phase synthesis are preferably dipolar and non-protic or non- polar. Examples of such solvents, include without limitation, dimethylforamide (DMF), dimethylsulfoxide (DMSO), dichloromethane, dichloroethane, and N-methyl morpholine. When persilylated nucleobases are utilized for solid phase synthesis, DMF is the preferred solvent.
  • the displacement reaction is preferably performed at atmospheric pressures. Typically, this reaction will take place at elevated temperatures between 20°C and 150°C; more typically, between 50°C and 11 °C; even more typically, between 60°C and 100°C; most typically, at about 80°C.
  • the time allowed for the components to react can vary depending on the temperature, pressure, reactants, and other components used.
  • the time can vary from 5 minutes to 24 hours.
  • the time given for the reaction is about 30 minutes to six hours; more preferably for 3 hours at 60°C-100°C and atmospheric pressure.
  • Synthesis of the monomer is complete after the nucleobase is incorporated into the monomer.
  • the second amino group of the displacing agent bound to the substrate is deprotected to permit acylation with the next acyl submonomer.
  • the same acyl and displacing submonomers need not be used throughout the oligomer.
  • the backbones of each monomer in the oligomer can vary if desired. Further, synthesis of monomers and oligomers can be automated utilizing peptide synthesizers, such as
  • PNAs of the instant invention can be utilized for diagnostic and therapeutic purposes.
  • PNA oligomers can be used as probes in standard polynucleotide detection and analytical procedures, such as Southerns and Northerns. As shown in the
  • the instant PNAs can be employed in a PCR assay to detect mutations. Such an assay is described in Orum et al., Nuc Acids Res 2K23V 5332-5336 (1993). Further, PNAs of the instant invention can be applied in anti-sense therapy. For example, a PNA can be designed to bind to an undesired cancer gene. By binding to the gene, the PNA can prevent transcription and/or translation of the gene to prevent cancer activation.
  • PNAs can also be used to bind materials other than polynucleotides.
  • PNAs can be designed to bind irreversibly to viral polymerase, like HTV, to prevent viral replication.
  • the oligomer was synthesized by incorporating monomers utilizing a four-step cycle. First, a resin-bound amine is acylated with a haloacetic acid submonomer acylating agent.
  • the halo leaving group is displaced with a monoprotected ethylenediamine submonomer displacing agent.
  • the unprotected amino group is acylated with a nucleobase derivative, a submonomer nucleobase agent.
  • the protected amino group is deprotected to permit the next round of monomer incorporation.
  • the resin used was fluorenylmethoxycarbonyl-4-methoxy-4'-( ⁇ -carboxypropyloxy)-benzhydryl- amine linked to alanyl-aminomethyl resin, the resin comprising chloromethylated polystyrene,
  • the resin was washed three times with 1 mL of dimethylformamide (DMF).
  • the deprotection of the 9-fluorenylmethoxycarbonyl (Fmoc) group was performed with 20% (v/v) piperidine, in DMF. After one prewash with this reagent, the resin was bubbled with argon for 30 minutes. To remove the reagent, the resin was drained and washed first with 1 mL DMF five times.
  • the resin was washed several times with DMF, by adding the solvent to the resin, agitating the mixture with argon, and drained.
  • a ten fold excess of the acyl submonomer, bromoacetic acid, and activating agent, carbod ⁇ mide, in DMF was added to the substrate bound amine.
  • 0.5 M bromoacetic acid, 0.5 M carbod ⁇ mide in DMF was added to the resin, and the mixture was agitated for approximately 30 minutes by bubbling argon through the mixture.
  • the solution was drained from the resin, and the resin was washed several times with DMF. Before beginning the displacement step, the resin was washed several times with
  • the resin was washed several times with a l l mixture of DMSO and N-methyl morpholine.
  • a ten fold excess of the nucleobase submonomer, 5- carboxymethyl-thymine was added.
  • the activating agent, PyBroP was added in powder form to the resin.
  • 1.0 mL of a 0.5 M solution of 5-carboxymethyl-thymine in DMSO/N-methyl morpholine (1:1) was added to the resin and the activating agent. When the solvent was added the activating agent was at a final concentration of 0.5 M and at 10 fold excess of the resin.
  • the resin and solution was agitated for approximately 30 minutes by bubbling argon.
  • the solution was drained from the resin, and the resin was washed several times with the 1 : 1 mixture of DMSO and N-methyl morpholine.
  • the second amino group of the displacing agent was deprotected.
  • the resin was washed three times with 1 mL of dichloromethane.
  • the deprotection of the Moz group was performed with 1% (v/v) trifluoroacetic acid (TFA), 2.5% (v/v) thioamisole and 2.5% (v/v) ethanedithiol in dichloromethane. After one prewash with this cleavage cocktail, the mixture was bubbled with the resin for 10 minutes.
  • the resin was drained and washed first with 1 mL dichloromethane three times. Next, the resin was washed with 10% (v/v) triethylamine in dichloromethane. The solution was then bubbled with a solution of 10% (v/v) triethylamine in dichloromethane for 10 minutes. After deprotection, the resin was washed several times with DMF. The three step cycle was repeated to construct a PNA octamer of oligothymine.
  • the oligomers dissolved in a buffer of 50 mM 3-N-morpholine-2hydroxy- propane sulfonic acid (MOPS), pH 7.0, 140 mM NaCl, and 10 mM MgCl 2 .
  • MOPS 3-N-morpholine-2hydroxy- propane sulfonic acid
  • pH 7.0 pH 7.0
  • 140 mM NaCl 140 mM NaCl
  • 10 mM MgCl 2 10 mM MgCl 2 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP95939958A 1994-11-14 1995-11-13 Herstellung von peptidnukleinsäuren (pnas) und analogen durch einsatzvon submonomeren Withdrawn EP0792283A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34007394A 1994-11-14 1994-11-14
US340073 1994-11-14
PCT/US1995/014821 WO1996015143A1 (en) 1994-11-14 1995-11-13 SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH

Publications (1)

Publication Number Publication Date
EP0792283A1 true EP0792283A1 (de) 1997-09-03

Family

ID=23331753

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95939958A Withdrawn EP0792283A1 (de) 1994-11-14 1995-11-13 Herstellung von peptidnukleinsäuren (pnas) und analogen durch einsatzvon submonomeren

Country Status (5)

Country Link
EP (1) EP0792283A1 (de)
JP (1) JPH10509947A (de)
AU (1) AU4159396A (de)
CA (1) CA2203565A1 (de)
WO (1) WO1996015143A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051697A2 (de) * 1997-05-14 1998-11-19 Morphochem Ag Verfahren zur herstellung von polymeren, die nucleobasen als seitengruppen aufweisen
DE69933770D1 (de) 1998-07-09 2006-12-07 Biocept Inc Verfahren zur verwendung einer universellen bibliothek von peptid-nukleinsäuren zur optimierung der dns-hybridisierung
WO2024081849A1 (en) * 2022-10-13 2024-04-18 Carnegie Mellon University Post-synthetic modification of polynucleotides via acylation reagents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228982B1 (en) * 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DE4331011A1 (de) * 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9615143A1 *

Also Published As

Publication number Publication date
AU4159396A (en) 1996-06-06
CA2203565A1 (en) 1996-05-23
WO1996015143A1 (en) 1996-05-23
JPH10509947A (ja) 1998-09-29

Similar Documents

Publication Publication Date Title
US6451968B1 (en) Peptide nucleic acids
US6441130B1 (en) Linked peptide nucleic acids
CA2183371C (en) Pna combinatorial libraries and improved methods of synthesis
US6201103B1 (en) Peptide nucleic acid incorporating a chiral backbone
US5714331A (en) Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US6613873B1 (en) Peptide nucleic acids having 2,6-diaminopurine nucleobases
US6403763B1 (en) Chiral peptide nucleic acids
US6172226B1 (en) Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
US20020115612A1 (en) Poly (N-substituted glycines) with nucleotide base substituents
EP0960121B1 (de) Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit
KR20030084444A (ko) Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
JP3595345B2 (ja) ペプチド核酸のモノマー及びオリゴマー
Kofoed et al. PNA synthesis using a novel Boc/acyl protecting group strategy
US6713602B1 (en) Synthetic procedures for peptide nucleic acids
WO1996015143A1 (en) SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH
US20030162699A1 (en) Chiral peptide nucleic acids with a n-aminoethyl-d-proline backbone
US20030157500A1 (en) Pyrrolidinyl peptide nucleic acids
US6710164B1 (en) Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1996020212A2 (en) Peptide nucleic acid incorporating a chiral backbone
US20030105286A1 (en) Linked peptide nucleic acids
US7098321B2 (en) Homologous peptide nucleic acids
Slaitas Development of a new PNA analogue as a potential antisense drug and tool for life-science studies
Vilaivana et al. Synthesis and Properties of Novel Peptide Nucleic Acids with Hydrophilic Serine Spacers
CA2180527A1 (en) Method of making polymers having specific properties
Dcosta Synthesis and evaluation of conformationally constrained pyrrolidyl polyamide nucleic acids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000601